The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients

Virology

Volumn 444, Issue 1-2, 2013, Pages 292-300

  Derbala, Moutaz ^a,b   Rizk, Nasser M ^c   Al Kaabi, Saad ^a   John, Anil ^a   Sharma, Manik ^a   El dweik, Nazeeh ^a   Yakoob, Rafie ^a   Pasic, Fuad ^a   Almohanadi, Muneera ^a   Alejji, Khalid ^a   Abdelmola, Abdulatif ^a   Butt, Mohamed ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c QATAR UNIVERSITY   (Qatar)

Author keywords

Genotype 4; HCV; IL28B polymorphis; IP 10

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; EGYPTIAN; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; VIRUS GENE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LOAD;

GENOTYPE 4; HCV; IL28B POLYMORPHIS; IP 10;

ADULT; ANIMALS; CHEMOKINE CXCL10; COHORT STUDIES; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84882875539     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.06.025     Document Type: Article

References (35)

1. Antaki N., Bibert S., Kebbewar K., Asaad F., Baroudi O., Alideeb S., Hadad M., Abboud D., Sabah H., Bochud P.Y., Negro F. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J. Viral. Hepatitis 2013, 20:59-64.
2. Askarieh G., Alsio A., Pugnale P., Negro F., Ferrari C., Neumann A.U., Pawlotsky J.M., Schalm S.W., Zeuzem S., Norkrans G., Westin J., Soderholm J., Hellstrand K., Lagging M., Ditto H.C.V., Groups N.O.S. Systemic and intrahepatic interferon-gamma-inducible protein 10kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010, 51:1523-1530.
3. Asselah T., De Muynck S., Broet P., Masliah-Planchon J., Blanluet M., Bieche I., Lapalus M., Martinot-Peignoux M., Lada O., Estrabaud E., Zhang Q., El Ray A., Vidaud D., Ripault M.P., Boyer N., Bedossa P., Valla D., Vidaud M., Marcellin P. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol. 2012, 56:527-532.
4. Balagopal A., Thomas D.L., Thio C.L. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010, 139:1865-1876.
5. Charles E.D., Dustin L.B. Chemokine antagonism in chronic hepatitis C virus infection. J. Clin. Invest. 2011, 121:25-27.
6. Chayama K., Hayes C.N., Abe H., Miki D., Ochi H., Karino Y., Toyota J., Nakamura Y., Kamatani N., Sezaki H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 2011, 204:84-93.
7. Cieśla A., Bocia{ogonek}ga-Jasik M., Sobczyk-Krupiarz I., Głowacki M.K., Owczarek D., Cibor D., Sanak M., Mach T. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World J. Gastroenterol.: WJG 2012, 18:4892.
8. Derbala M., Rizk N., Al-Kaabi S., Amer A., Shebl F., Al Marri A., Aigha I., Alyaesi D., Mohamed H., Aman H., Basem N. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment. J. Viral. Hepatitis 2009, 16:689-696.
9. Derbala M., Rizk N., Shebl F., Alkaabi S., Eldweik N., John A., Sharma M., Yaqoob R., Almohanadi M., Butt M., Alejji K. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J. Gastroenterol. 2012, 18:7003-7008.
10. El-Awady M.K., Mostafa L., Tabll A.A., Abdelhafez T.H., Bader El Din N.G., Zayed N., Shenawy R.E., El Abd Y., Hasan R.M., Zaghlol H., El Khayat H., Abdel Aziz A.O. Association of IL28B SNP with progression of Egyptian HCV Genotype 4 patients to end stage liver disease. Hepatitis Mon. 2012, 12:271-277.
11. El-Shamy A., Shoji I., El-Akel W., Bilasy S.E., Deng L., El-Raziky M., Jiang D.P., Esmat G., Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J. Clin. Microbiol. 2012, 50:3886-3892.
12. Fernandez-Arcas N., Lopez-Siles J., Trapero S., Ferraro A., Ibanez A., Orihuela F., Maldonado J., Alonso A. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J. Med. Virol. 2006, 78:1429-1435.
13. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
14. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
15. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E., Sakai Y., Yamashita T., Nakamura M., Shirasaki T., Horimoto K. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139:499-509.
16. Ito K., Higami K., Masaki N., Sugiyama M., Mukaide M., Saito H., Aoki Y., Sato Y., Imamura M., Murata K., Nomura H., Hige S., Adachi H., Hino K., Yatsuhashi H., Orito E., Kani S., Tanaka Y., Mizokami M. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol. 2011, 49:1853-1860.
17. Kamal S.M., Nasser I.A. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008, 47:1371-1383.
18. Lagging M., Askarieh G., Negro F., Bibert S., Soderholm J., Westin J., Lindh M., Romero A., Missale G., Ferrari C., Neumann A.U., Pawlotsky J.M., Haagmans B.L., Zeuzem S., Bochud P.Y., Hellstrand K., Group D.-H.S. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011, 6:e17232.
19. Li K., Li N.L., Wei D., Pfeffer S.R., Fan M., Pfeffer L.M. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012, 55:666-675.
20. Liu C.H., Liang C.C., Liu C.J., Tseng T.C., Lin C.L., Yang S.S., Su T.H., Lin J.W., Chen J.H., Chen P.J., Chen D.S., Kao J.H. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. Antiviral Therap. 2012, 17:1059-1067.
21. McCarthy J.J., Li J.H., Thompson A., Suchindran S., Lao X.Q., Patel K., Tillmann H.L., Muir A.J., McHutchison J.G. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
22. Miyamura T., Kanda T., Nakamoto S., Wu S., Jiang X., Arai M., Fujiwara K., Imazeki F., Yokosuka O. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses 2012, 4:1264-1278.
23. Papastergiou V., Dimitroulopoulos D., Skorda L., Lisgos P., Ketikoglou I., Kostas N., Karatapanis S. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?. J. Med. Virol. 2012, 84:1217-1223.
24. Pedergnana V., Abdel-Hamid M., Guergnon J., Mohsen A., Le Fouler L., Theodorou I., Mohamed M.K., Fontanet A., Plancoulaine S., Abel L. Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. PLoS One 2012, 7:e38578.
25. Rallon N.I., Soriano V., Naggie S., Restrepo C., McHutchison J., Vispo E., Benito J.M. Impact of IL28B gene polymorphisms on interferon-lambda3 plasma levels during pegylated interferon-alpha/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J. Antimicrob. Chemother. 2012, 67:1246-1249.
26. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Gunthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(1338-1345):1345 e1331-1337.
27. Rizk N.M., Derbala M.F. Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4. Clin. Res. Hepatol. Gastroenterol 2012.
28. Romero A.I., Lagging M., Westin J., Dhillon A.P., Dustin L.B., Pawlotsky J.M., Neumann A.U., Ferrari C., Missale G., Haagmans B.L., Schalm S.W., Zeuzem S., Negro F., Verheij-Hart E., Hellstrand K., Group D.-H.S. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J. Infect. Dis. 2006, 194:895-903.
29. Shalaby S.M., Radwan M.I., Abdelazim S., Nafee A.M. Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients. Cell. Immunol. 2012, 276:110-113.
30. Shi X., Pan Y., Wang M., Wang D., Li W., Jiang T., Zhang P., Chi X., Jiang Y., Gao Y., Zhong J., Sun B., Xu D., Jiang J., Niu J. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012, 7:e37054.
31. Stattermayer A.F., Stauber R., Hofer H., Rutter K., Beinhardt S., Scherzer T.M., Zinober K., Datz C., Maieron A., Dulic-Lakovic E., Kessler H.H., Steindl-Munda P., Strasser M., Krall C., Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011, 9(344-350):e342.
32. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
33. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(120-129):e118.
34. Yoneda S., Umemura T., Katsuyama Y., Kamijo A., Joshita S., Komatsu M., Ichijo T., Matsumoto A., Yoshizawa K., Ota M., Tanaka E., Nagano Interferon Treatment Research G. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J. Infect. Dis. 2011, 203:1087-1095.
35. Zhang L., Miao L., Han F., Dou X.G. Cytokine levels in serum of patients with chronic hepatitis C and its significance. Xi bao yu fen zi mian yi xue za zhi=Chinese J. Cell. Mol. Immunol. 2011, 27:301-303.